Peptron Inc
KOSDAQ:087010
Peptron Inc
Total Current Liabilities
Peptron Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Total Current Liabilities
₩7.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
10%
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Total Current Liabilities
₩3.8T
|
CAGR 3-Years
-3%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
A
|
ADM Korea Inc
KOSDAQ:187660
|
Total Current Liabilities
₩10.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Total Current Liabilities
₩147.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Total Current Liabilities
₩14.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Total Current Liabilities
₩66.4B
|
CAGR 3-Years
70%
|
CAGR 5-Years
50%
|
CAGR 10-Years
59%
|
|
Peptron Inc
Glance View
Peptron Inc., a biotechnology firm based in South Korea, is weaving a narrative of innovation that marries cutting-edge research with real-world applications. Founded in 1997, the company has carved a niche in the realm of peptide-based pharmaceuticals, focusing on the formulation and delivery of these potent compounds for chronic diseases. Central to its story is the SmartDepot™ technology, a proprietary drug delivery system that ensures precise, sustained release of medication. This technology not only enhances patient compliance by reducing the frequency of dosing but also maximizes therapeutic efficacy, positioning Peptron as a trailblazer in improving patient care. At the heart of Peptron's business model is its ability to capitalize on its advanced drug delivery systems by collaborating with global pharmaceutical giants and seeking strategic partnerships. With a robust pipeline, including promising treatments for Parkinson's disease and various endocrine disorders, Peptron generates revenue through licensing deals, co-development agreements, and the eventual commercialization of its therapeutics. By balancing research innovation with savvy business collaborations, Peptron is not just navigating the competitive biotech landscape; it is rewriting the narrative on harnessing technology for transformative healthcare solutions.
See Also
What is Peptron Inc's Total Current Liabilities?
Total Current Liabilities
7.3B
KRW
Based on the financial report for Sep 30, 2025, Peptron Inc's Total Current Liabilities amounts to 7.3B KRW.
What is Peptron Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
10%
Over the last year, the Total Current Liabilities growth was 4%. The average annual Total Current Liabilities growth rates for Peptron Inc have been -16% over the past three years , -24% over the past five years , and 10% over the past ten years .
